Above and Beyond Concierge Therapeutics is a precision medicine company dedicated to discovering and translating new therapies for nervous system diseases at an accelerated pace. Its precision medicine program enables new target discovery for individual patients through genetic screening and stem cell approaches.

Established in 2012 by Governor Brown, GO-Biz serves as California’s single point of contact for economic development and job creation efforts, offering a range of services to business owners including: attraction, retention and expansion services, permit streamlining, regulatory assistance, business assistance, international trade dev., assistance with state gvmt., etc.

The CMT Research Foundation is focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease. Founded by two patients who are driven to expedite drug delivery to people who live with CMT globally, the organization funds research and drug development.

Icagen is an integrated early discovery partner, offering clients specialized technologies and deep scientific expertise to solve myriad challenges and optimize efficiency moving from target to lead. We work in multi-year, integrated programs, as well as individual projects to fill gaps in R&D efforts. 

Ichida Lab creates in vitro models of human neurodegenerative diseases by converting patients’ skin fibroblasts into disease-affected neural cells. This enables them to screen thousands of drug-like compounds in search of potential therapeutics that slow or stop the degeneration of these cells in petri dishes — and eventually in patients.

Keiretsu is a global angel investor network with more than 2500 accredited investor members. Keiretsu’s worldwide network is extensive and includes 52 chapters on 3 continents. Members invest in high-quality, diverse opportunities, and are ranked as the most active venture investors in the USA.

The Muscular Dystrophy Association is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases through innovations in science and care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since its inception to accelerate the discovery of therapies and cures.

Viva BioInnovator (VBI) is the investment division of Viva Biotech Holdings (1873.HK), dedicated to the identification and success of early-stage, biotech start-ups for VBI’s incubation, equity-for-service, and investment platforms. VBI's commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.